Chimin Health Management

What Chimin Health Management does

Chimin Health Management Co., Ltd. (济民健康管理股份有限公司, SSE: 603222.SH) is a publicly listed Chinese pharmaceutical and medical device group founded in 1996 in Taizhou, Zhejiang Province, with registered capital of RMB 5.3 billion and seven wholly-owned subsidiaries. The company operates a 'one main and two wings' structure built around three segments: chemical pharmaceuticals (large-volume IV solutions in non-PVC soft bag, plastic bottle, and PP bottle formats, covering sodium chloride, glucose, mannitol, compound sodium lactate, Ringer's, and physiological saline across roughly 40 SKUs); medical devices (self-destroying safety syringes developed with US RTI/UNICEF channel access, pre-filled catheter flushers for PICC maintenance, hemodialysis concentrate solutions, and in vitro diagnostics including FOB fecal occult blood and H. pylori test kits from the Spanish LINEAR Chemicals subsidiary); and healthcare services (three owned hospitals: Boao International Hospital in Hainan Boao Lecheng pilot zone with PMDA-certified regenerative medicine labs, Ezhou Second Hospital in Hubei with a 1,000-bed Grade 3 standard south campus, and Baishui County Jimin Hospital in Shaanxi).

The company's technology base is anchored in proprietary non-PVC film formulation (designated a National Torch Plan Project), double-tube double-valve multi-layer co-extrusion film soft bags, and a portfolio of 78 patents including 19 invention patents. International expansion includes long-term cooperation with a US medical device giant and exports to Middle East, South America, Southeast Asia, and Africa, with regulatory certifications spanning China GMP, US FDA, and Japan PMDA. The Boao International Hospital leverages Japanese regenerative medicine expertise (President Mr. Oda Harunori), Stanford and University of Turin honorary leadership, and affiliated status with Shanghai University of Traditional Chinese Medicine to position within China's cross-border medical tourism framework.

The business model combines B2B hardware sales (medical devices and IV solutions sold through direct sales teams covering 25 provinces plus international distributors), managed healthcare services revenue from owned hospitals, and government-tender channel access via UNICEF/RTI. Pricing is quote-based and negotiated rather than publicly disclosed. The group is family-controlled, with the Li Xianyu (李仙玉) family holding direct and indirect stakes through Shuangge Group (双鸽集团), the controlling shareholder. Reported financials indicate declining revenue and profitability stress through 2024-2025.

Name

Chimin Health Management

Legal name

济民健康管理股份有限公司

Website

https://chimin.cn

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Chimin Health Management is a Shanghai-listed Chinese pharmaceutical and medical device manufacturer operating across IV solutions, safety injection devices, in vitro diagnostics, and three owned hospitals. Founded 1996, it serves domestic healthcare providers across 25 provinces and exports to Middle East, South America, Southeast Asia, and Africa.

Ownership category

akta.pro rank

Product category

Pharmaceuticals & Medical Devices

NAICS

Medical and Diagnostic Laboratories (62151), Other Ambulatory Health Care Services (6219)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-General Medical & Surgical Hospitals, Nec (8062), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Services-Medical Laboratories (8071)

akta.pro primary industry

Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)

akta.pro secondary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

Keywords

• Intravenous infusion solutions
• Safety injection devices
• In vitro diagnostics
• Hemodialysis products
• Hospital healthcare services

Headquarters

HQ city

Huangyan

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Devices Manufacturing: Core business segment including safety injection/puncture devices, pre-filled catheter flushers, in vitro diagnostic products, and hemodialysis concentrate solutions. Over 30 years of experience in injection/puncture devices, leading domestic market position in safety syringes.
2. Healthcare Services (Hospital Operations): Operation of 3 comprehensive hospitals: Boao International Hospital in Hainan, Ezhou Chengnan Hospital, and Ezhou Second Hospital. Focus on oncology, nephrology, cardiovascular, and other specialty areas.
3. Chemical Pharmaceuticals (IV Solutions): Nearly 40 types of IV solutions including balanced solutions, nutritional solutions, therapeutic solutions, and external irrigation solutions. Non-PVC soft bag, plastic bottle, and PP bottle packaging formats.
4. Export/International Trade: International export of IV solutions and medical devices to Middle East, South America, Southeast Asia, and Africa markets through subsidiary companies and international partnerships.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Chimin Health Management manufactures and sells large-volume intravenous (IV) infusion solutions, safety injection devices (including self-destroying syringes), in vitro diagnostic products, hemodialysis concentrate solutions, and pre-filled catheter flushers. The company also operates three hospitals (Boao International Hospital, Ezhou Second Hospital, and Baishui County Jimin Hospital) providing specialty healthcare services including regenerative medicine, oncology, nephrology, and cardiovascular care.

Product overview

Chimin Health Management is a modern pharmaceutical listed company with a comprehensive product and service portfolio organized across three main segments: (1) Chemical Pharmaceuticals – large volume injections covering non-PVC dual-tube dual-valve, single-tube single-valve, and single-tube dual-valve soft bags, PP plastic bottles, including sodium chloride, glucose, mannitol, compound sodium chloride, compound sodium lactate glucose, sodium lactate Ringer's solutions, and physiological saline (approximately 40+ infusion varieties); (2) Medical Devices – including safety injection/puncture devices (needle tip auto-retractable self-destroying syringes, safety needles, sterile syringes, infusion sets), in vitro diagnostics (FOB fecal occult blood tests, H. pylori test kits, clinical chemistry reagents), hemodialysis concentrates (A/B solutions and powders), and pre-filled catheter flushers; (3) Healthcare Services – operating three comprehensive hospitals: Boao International Hospital (Hainan), Ezhou Second Hospital (Hubei), and Baishui County Jimin Hospital (Shaanxi). The company has built a 'one main and two wings' strategic layout with medical devices as the core business, supported by healthcare services and chemical pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Brands

• 双鸽 (Shuangge): Primary brand for injection and transfusion medical devices. '双鸽' brand syringes have nearly 30 years of history, with一次性无菌注射器 and 一次性使用输液器 awarded China Famous Brand. 2020 浙江出口名牌.
• 博鳌国际医院

Products and services

• Large Volume IV Infusion Solutions A portfolio of approximately 40 large-volume IV infusion solutions (sodium chloride, glucose, mannitol, compound sodium chloride, compound sodium lactate and glucose, sodium lactate Ringer's, and physiological saline) used for fluid/electrolyte replacement, energy supplementation, dehydration treatment, diuresis, and irrigation. Packaged in non-PVC soft bags, PP bottles, and plastic bottles. Sold to hospitals, clinics, and healthcare providers.
• Safety Injection Devices Series Safety syringes including automatic needle-retractable self-destroying syringes, sterile syringes, insulin syringes, safety needles, and infusion sets. Core product is auto-retractable safety syringe co-developed with US RTI company (UN/UNICEF supplier). Sold to hospitals, vaccination programs, and healthcare providers.
• In Vitro Diagnostic (IVD) Products Clinical chemistry reagents, immunological diagnostics, blood test reagents, rapid diagnostic tests, enzyme-linked immunoassay diagnostic reagents, laboratory instruments. Core products: FOB fecal occult blood auto-immune detection kit and H. pylori test kit, both with EU patents. Distributed to hospitals, diagnostic labs, and clinics.
• Hemodialysis Concentrate Solutions Hemodialysis concentrate products including Solution A, Solution B, A powder, B powder, and online dry powder bucket (B powder bucket). Produced with ultra-pure water beyond dialysis water technical specifications in C+A cleanroom environment with automated equipment. Sold to dialysis centers and hospitals.
• Pre-filled Catheter Flusher Drug-device combination product for PICC (peripherally inserted central catheter) and indwelling needle maintenance, replacing traditional saline/heparin flushing solutions. Offers simplified operation, reduced material consumption, lower infection risk, reduced needlestick injuries, and improved workflow efficiency. Sold to hospitals and infusion therapy providers.
• Boao International Hospital International medical hospital in Hainan Boao Lecheng International Medical Tourism Pilot Zone. Features international regenerative medicine research center (stem cell labs, immune cell labs, molecular diagnostics, gene diagnostics) certified by Japanese Ministry of Health, Labour and Welfare. Offers regenerative medicine, cell therapy, cancer treatment, health examinations, integrated medical care, research, prevention, health management, and elderly care. Equipped with PET/CT, MRI, CT, and DSA facilities.
• Ezhou Second Hospital (Ezhou Chengnan Hospital) Comprehensive Grade 2 hospital in Ezhou, Hubei (established 1953) with north and south campuses. North campus: 200 beds, 400+ staff, 127 senior medical personnel. South campus (Ezhou Chengnan Hospital): 42,880 sqm land, 110,000 sqm building area, 1,000 beds, built to tertiary hospital standards. Key departments: oncology, nephrology, cardiovascular, obstetrics, minimally invasive surgery, orthopedics, endocrinology, neurology.

Quantifiable outcome

• Double-tube double-valve multi-layer co-extrusion film soft bag project recognized as National Torch Plan Project
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• Shanghai University of Traditional Chinese MedicinecoreStrategic or Co-development Partner · 6 August 2020Boao International Hospital became affiliated hospital of Shanghai University of TCM in August 2020. Strategic cooperation in TCM and biotechnology, elderly health services, talent cultivation, and international exchange in Chinese medicine.
• LINEAR CHEMICALS S.L. (Spain)coreStrategic or Co-development Partner · 19 May 2016Acquired 100% equity for EUR 4,987,500 in May 2016. LINEAR specializes in in vitro diagnostics including FOB fecal occult blood test and H. pylori test kits with EU patents. This acquisition enhanced company's IVD capabilities and international market access.
• RTI (United States)coreTechnology or IntegrationCollaboration with US RTI company for safety injection devices. RTI is a UN supplier (UNICEF supplier). Jointly developed safety syringes including needle-retraction self-destroying syringes. Technology level internationally advanced.
• Hainan Medical University Second Affiliated HospitalmajorStrategic or Co-development PartnerCooperation to enhance hospital technical capabilities and competitiveness. Established surgical platform, disinfection supply platform, critical care platform, and 5 medical project groups including oncology, orthopedics, neurology, liver disease, and endocrinology.
• Korean FACmajorTechnology or IntegrationInvested over USD 10 million with Korean FAC for automated production line development achieving 3600-4500 bags/hour output for IV solutions.
• Japan Medical法人医进会 (Mr. Oda)coreStrategic or Co-development PartnerJapanese regeneration medicine expert Mr. Oda Harunori serves as Boao International Hospital President. Full Japanese technical expert management of cell preparation labs according to international standards.
• Stanford University (Translational Medicine Center)majorStrategic or Co-development PartnerDean W. Felsher from Stanford University Translational Medicine Center serves as Boao International Hospital Honorary President. Academic exchange and cooperation.
• Italy University of TurinmajorStrategic or Co-development PartnerProfessor Pier Maria Furlan, Acting Dean of University of Turin Medical School, serves as Honorary President. Medical technology and academic exchange.
• Singapore Asian Medical GroupmajorStrategic or Co-development PartnerCooperation on transplant center and minimally invasive surgery center. First international medical specialty center in Lecheng pilot zone opened.
• Chongqing University Affiliated Three Gorges HospitalmajorStrategic or Co-development PartnerEstablished Boao International Medical Department of Three Gorges Hospital in Lecheng zone for technology cooperation.
• US Medical Device GiantcoreStrategic or Co-development PartnerLong-term strategic cooperation with unnamed US medical device giant for product development and international market expansion.
• Domestic Universities and Research InstitutionsmajorStrategic or Co-development PartnerLong-term strategic cooperation with multiple domestic universities and research institutions for R&D collaboration and technology transfer in pharmaceuticals and medical devices.

Scale indicators12 records

Recent moves9 records

Expansion highlights5 records

Regional players

• Shinva Medical Instrument: Chinese-listed medical device manufacturer (SHA: 600587) producing syringes, infusion sets, and other disposable medical devices. Most direct Chinese peer to Chimin in the safety syringe and IV equipment categories, serving overlapping domestic hospital customers.
• Lepu Medical Technology: Chinese-listed medical device company (SHE: 300003) covering interventional cardiology, structural heart disease, and IVD — partially comparable to Chimin's medical device and IVD segments. Both serve Chinese hospital channels and pursue international expansion.

Direct peers

• ICU Medical: US-listed medical device company specializing in IV therapy, safety syringes, and needle-free connectors — directly comparable to Chimin's safety injection device and pre-filled catheter flusher product portfolio. Competes with Chimin in the safety injection segment globally.

Broad incumbents

• Baxter International: Global medical products company specializing in IV solutions, infusion pumps, and sterile fluids — the same large-volume parenteral and infusion product space that anchors Chimin's chemical pharmaceutical segment. Comparable on IV bag technology, packaging formats, and hospital channel access.
• China Resources Pharmaceutical Group: State-owned Chinese pharmaceutical conglomerate covering drug manufacturing, distribution, and healthcare services. Comparable to Chimin's diversified pharma+device+hospital model, though at much greater scale with state backing.
• B. Braun Melsungen: German medical device and pharmaceutical company with a major IV solutions and infusion systems business, including safety injection devices. Comparable to Chimin on the chemical pharmaceutical (IV solutions) and medical device (safety syringes) segments, with similar hospital-focused distribution model.
• Fresenius Kabi: Global leader in clinical nutrition, IV drugs, and medical devices including infusion solutions and hemodialysis products. Directly comparable to Chimin across the IV solutions franchise, hemodialysis concentrate line, and clinical nutrition product set.
• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical distributors and manufacturers with a broad drug and medical device portfolio. Comparable to Chimin on the chemical pharmaceutical manufacturing side, though much larger and more diversified across the full pharma value chain.
• Shandong Weigao Group Medical Polymer: Chinese-listed medical device conglomerate (HKEX: 1066) manufacturing single-use medical consumables including syringes, IV sets, and prefilled catheters. Directly comparable to Chimin on the safety syringe and pre-filled flusher product lines, though Weigao is significantly larger and more diversified across orthopedics and blood collection.

Emerging players

• Haemonetics: US-listed company focused on blood and plasma component management, with blood bank and transfusion medicine products. Tangentially comparable to Chimin's IV solutions/transfusion-adjacent product line, especially useful as a reference for the hemodialysis and blood-related medical device categories.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chimin Health Management